ライフサイエンスコーパス: OGTT

1 OGTT results were available in all patients at baseline,

2 9.03 +/- 4.15 vs. 15.68 +/- 6.48, p = 0.016; OGTT 60': 13.33 +/- 5.40 vs. 17.37 +/- 3.16 vs. 15.84 +/

3 n NGT obese and 11 T2DM subjects received 1) OGTT, 2) euglycemic insulin clamp with muscle biopsy, an

4 in subjects who had a mean (SD) of 6.4 (3.2) OGTTs during 22.1 (8.0) years of follow-up.

5 our blood glucose after glucose overload (2h-OGTT), HbA1c, triglyceride (TG) levels and HOMA-IR and p

6 Of the 585 OGTTs performed on islet cell antibody (ICA)-positive re

7 The proportion of patients with an abnormal OGTT increased from 42% at baseline to 61% at follow-up

8 These pigs were subjected to an additional OGTT at 22 wk.

9 LP-1 levels increased both at fast and after OGTT mainly in type 2 diabetic subjects.

10 42% women, BMI 30 kg/m(2)) before and after OGTT.

11 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lo

12 lic acid cycle intermediates decreased after OGTT, and glycolysis products increased, consistent with

13 fasting insulin, glucose level at 2 h after OGTT, and HOMA-IR.

14 in mean (SEM) insulin AUC 120 minutes after OGTT (-2930 [912] vs -414 [432] microIU/mL [-20349 6334

15 An OGTT and IVGTT were repeated during the 12th week of tre

16 0.33, P = 0.02), insulin secretion across an OGTT (men R = 0.46, P = 0.01; women R = 0.40, P = 0.004)

17 mately 50% to the insulin excursion after an OGTT with and without DPP-4 inhibition.

18 A KE drink consumed before an OGTT lowered glucose and NEFA AUCs with no increase in c

19 e-phase insulin secretion, as revealed by an OGTT.

20 e area under the curve for glucose during an OGTT, and liver fat.

21 hyperglycemia and hyperinsulinemia during an OGTT, HFD-fed rats that co-used alcohol and THC had the

22 During an OGTT, no differences were observed in glucose, insulin a

23 and 2-h glucose concentrations following an OGTT were associated with 242, 1, 592, and 17 differenti

24 ell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosigl

25 d the inclusion criteria, of whom 122 had an OGTT (91% of cohort).

26 n 5.6 and 6.9 mmol/L were invited to have an OGTT.

27 These findings suggest routine use of an OGTT in renal transplant recipients is a valuable clinic

28 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2

29 athways that are perturbed in response to an OGTT.

30 ned with periodic metabolic testing using an OGTT.

31 The estimation of beta-cell function with an OGTT before surgery can identify patients at risk for de

32 ternational Diabetes Federation criteria and OGTT was interpreted according to the WHO classification

33 Fasting, 24-h, and OGTT insulin levels were similar between groups througho

34 999 to 2011, measurements of fPG, HbA1c, and OGTT were performed in 1,619 nondiabetic renal transplan

35 Intravenous glucose tolerance test IVGTT and OGTT insulin secretion rate (ISR) and sensitivity were o

36 ctisole was included in both the preload and OGTT solutions.

37 s rs1799884 (GCK) and rs7903146 (TCF7L2) and OGTT outcomes at 24-32 weeks' gestation in 3,811 mothers

38 ovariates, maternal body mass index (BMI) at OGTT, maternal height at OGTT, maternal mean arterial pr

39 mass index (BMI) at OGTT, maternal height at OGTT, maternal mean arterial pressure at OGTT, maternal

40 ovariates, maternal glucose and C-peptide at OGTT.

41 at OGTT, maternal mean arterial pressure at OGTT, maternal smoking and drinking; Model 3 adjusted fo

42 HbA1c, basal OGTT, and 1- and 2-hour OGTT were positively related to

43 Because of the lack of agreement between OGTT results and HbA1c levels, models were created to an

44 Other pathways affected by OGTT included decreases in serotonin derivatives, urea c

45 nd one of four cases of PTDM was detected by OGTT alone.

46 dless of the diagnosis of IGT or diabetes by OGTT.

47 tolerance, especially for IGT and new DM by OGTT compared with AIR.

48 ique metabolic phenotypes can be unmasked by OGTT in the prediabetic state.

49 y rate (P = 0.020) compared with the control OGTT.

50 Combining 3- and 12-month data, OGTT recorded NODAT in 14% and impaired glucose toleranc

51 72 showed association with 30' Deltainsulin (OGTT 30' min fasting insulin) in an interaction with per

52 mal OGTTs (NLOGTT), while transient diabetic OGTTs (TDOGTTs) were compared with subsequent nondiabeti

53 During OGTT, 18 patients who had a blood glucose nadir of <69 m

54 During OGTT, cortisol and DHEA increased after the third hour a

55 During OGTT, glucose area under the curve (AUC) was higher and

56 During OGTT, incremental area under the curve (AUC) for insulin

57 During OGTT, IT-operated animals exhibited lower plasma glucose

58 During OGTT, we measured hepatic (HGU) and adipose tissue (ATGU

59 20 min (fold change glucagon120/0 <1) during OGTT, whereas 21-34% presented with increasing glucagon

60 er SI higher glucose and insulin AUCs during OGTT, and higher triglyceride levels, independent of tot

61 sma glucose and 1-hour plasma glucose during OGTT.

62 ntation did not affect plasma insulin during OGTT challenge (BCAA: -3.9% +/- 8%; low-BCAA: 14.8% +/-

63 sitive integer of the AUC for insulin during OGTT did not differ between trials (HYPER 55,850 +/- 36,

64 for 0-120 min for glucose and insulin during OGTT, Quantitative Insulin Sensitivity Check Index, Simp

65 reduces plasma free fatty acid levels during OGTT.

66 Glucagon levels were measured during OGTT in a total of 4,194 individuals without diabetes in

67 nsulin, and c-peptide values measured during OGTT.

68 o quantify insulin-secretory profiles during OGTT and glucose infusion protocols.

69 0-min but not 30-min insulin response during OGTT.

70 ressive impairment in FFA suppression during OGTT, whereas the rise in mean plasma glucose concentrat

71 ps), the change in total glucose area during OGTTs (P = 0.58), or the change in fractional glucose di

72 mental insulin response (30-min dINS) during OGTTs.

73 ant (P < 0.001), and with a reduction during OGTTs, which approached statistical significance (P = 0.

74 Dysglycemic OGTTs (DYSOGTTs) were compared with normal OGTTs (NLOGTT

75 s compared with control HF animals following OGTT.

76 obtained 2 h after a glucose load given for OGTT (r = 0.69, P = 0.001).

77 itivity more than 94%, avoiding the need for OGTT in 49% of patients.

78 velop diabetes during the trial returned for OGTTs and IVGTTs 8 months after study medications were s

79 ) and insulin sensitivity were assessed from OGTT.

80 d to screen women for those requiring a full OGTT.

81 plasma glucose concentration from the 100-g OGTT at which GDM was diagnosed (higher = increased risk

82 remental insulin:glucose ratio during a 75-g OGTT (P = 0.0002) and the total area under the diagnosti

83 ental plasma insulin:glucose ratio on a 75-g OGTT and the insulin sensitivity index from a hyperinsul

84 Ten minutes before the 75-g OGTT, participants consumed a preload solution of either

85 85 nondiabetic British subjects after a 75-g OGTT.

86 between 1 and 6 months postpartum for a 75-g OGTT.

87 ontrol drink 30 min before completing a 75-g OGTT.

88 ssification was evaluated using 2-hour, 75-g OGTTs.

89 the increment in plasma insulin to glucose [OGTT/IR (DeltaI/DeltaG / IR)]).

90 Bed rest increased 2-h OGTT blood glucose and insulin independent of genetic va

91 n 87 subjects, and diabetes was found by 2-h OGTT criteria alone in 61 subjects.

92 jects with IGT and subjects diagnosed by 2-h OGTT criteria alone.

93 hen substituting alpha-HB and L-GPC with 2-h OGTT glucose concentrations.

94 Similarly, each 1-mmol/L increase in 2-h OGTT glucose was associated with higher neonatal sSAT (0

95 ired glucose tolerance, with fasting and 2-h OGTT insulin values increasing by 2.3-fold (P < 0.001) a

96 However, both basal and 2-h OGTT serum insulin were significantly correlated with SA

97 43.48% of placebo patients had a normal 2-h OGTT, with the absolute risk reduction 18.06%.

98 of HbA1c (beta = 0.08%; P = 0.03) and 2-hour OGTT glucose concentrations (beta = 0.25 mmol/L; P = 0.0

99 VLDL cholesterol, triglycerides, and 2-hour OGTT were higher in patients with periodontitis than in

100 HbA1c, basal OGTT, and 1- and 2-hour OGTT were positively related to prepregnancy BMI and blo

101 HbA1c, triglycerides, and 1- and 2-hour OGTT were positively related with probing depth and clin

102 hirteen Glut1-DS patients completed a 5-hour OGTT.

103 No significant changes in OGTT responses were observed.

104 dition, there was a trend for a reduction in OGTT insulin area under the curve (-15,567 +/- 3,658 pmo

105 be different genes influencing variation in OGTT measures of insulin secretion and insulin resistanc

106 An initial OGTT was performed at a mean (+/-SD) gestation of 15.6+/

107 ams/L), basal glucose (-0.9 +/- 0.8 mmol/L), OGTT glucose area under the curve (-158 +/- 164 mmol/L),

108 els increased overall from the first to last OGTTs before diagnosis (P < 0.001 at every time point, n

109 We evaluated Adipo-IR (fasting and mean OGTT plasma free fatty acid [FFA] x insulin concentratio

110 owever, the insulin response (IGR) at 60-min OGTT was significantly lower in T-allele carriers (P = 3

111 ever, the nutrient-induced delta (meal minus OGTT) in insulin secretion and glucagon concentrations d

112 sted of 53 living subjects who had 2 or more OGTTs and underwent brain 11C-PiB positron emission tomo

113 Of 135 progressors with four or more OGTTs, 30 (22%) went from NLOGTTs to DYSOGTTs at least t

114 In analysis of vascular disease risk, new OGTT-diagnosed diabetes cases with and without diagnosti

115 and subsequent (within 3 months) nondiabetic OGTTs in 55 progressors.

116 s) were compared with subsequent nondiabetic OGTTs and with OGTTs performed at diagnosis.

117 c OGTTs (DYSOGTTs) were compared with normal OGTTs (NLOGTT), while transient diabetic OGTTs (TDOGTTs)

118 the diabetes-free population, replacement of OGTT with HbA1c-based diagnosis appears justified.

119 n sensitivity, as illustrated by a return of OGTT glucose and insulin values and maximal GDR to near-

120 ant recipients and supports continued use of OGTT as a diagnostic tool for detection of PTDM.

121 nderwent transplant surgery within 1 year of OGTT and had a repeat OGTT 3-6 months after transplantat

122 re measured concurrently with performance of OGTTs in the same study.

123 iabetes was diagnosed by the 2-h criteria on OGTT alone.

124 demonstrated associations with at least one OGTT trait in nondiabetic individuals; 80 SNPs were nomi

125 After baseline oral (OGTT) and intravenous (IVGTT) glucose tolerance testing,

126 at which time 4 p.m. CapBG also outperformed OGTT.

127 men provided data from a total of 280 paired OGTTs and IVGTTs during a median follow-up of 46 months.

128 status was assessed by fasting and 2-h post-OGTT glucose and glycated hemoglobin (HbA(1c)).

129 respectively (P for trend = 0.003); 2-h post-OGTT glucose: 106.3 and 101.9 mg/dL, respectively (P for

130 and glycemic status, as measured by 2-h post-OGTT insulin and glucose and ISI(0,120), after adjustmen

131 characteristics, and diet quality [2-h post-OGTT insulin: lowest and highest quintile, 81.0 and 72.7

132 abolic effects were distinct, including post-OGTT C-peptide concentrations and aspects of energy meta

133 Although postprandial (OGTT) glucose and fasting cholesterol concentrations wer

134 Based on postsurgery OGTT, subjects were divided into 3 groups depending on g

135 Among 205 participants with previous OGTT data, greater severity and longer duration of hyper

136 Prolonged OGTT in four available patients and matched control subj

137 A repeat OGTT (Post-JD) was performed after completion.

138 rgery within 1 year of OGTT and had a repeat OGTT 3-6 months after transplantation.

139 ying HbA1c as a screening test and reserving OGTT for those with impaired glucose tolerance would det

140 luster and response to an oral glucose test (OGTT) and oral fat load test (OFTT) in the EARSII group

141 betic by a 75-g oral glucose tolerance test (OGTT) (65 had NGT and 60 had IGT).

142 ) . min) and an oral glucose tolerance test (OGTT) (75 g) on separate days.

143 had an abnormal oral glucose tolerance test (OGTT) (P = 0.03) before and a higher frequency of oral h

144 and the average oral glucose tolerance test (OGTT) 2-h glucose measurement over previous BLSA visits.

145 sted with a 5-h oral-glucose-tolerance test (OGTT) and a euvolemic, euenergetic protein challenge.

146 subjected to an oral glucose tolerance test (OGTT) and a mixed-meal test (MMT) before and after 12 wk

147 nical study, an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT)

148 henotyped by an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test and by a

149 essed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose clamp (iso-

150 received a 75-g oral glucose tolerance test (OGTT) and euglycemic insulin (80 mU x m(-2) x min(-1)) c

151 nce received an oral glucose tolerance test (OGTT) and euglycemic insulin clamp.

152 rance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were perfor

153 had a 2-h 75-g oral-glucose-tolerance test (OGTT) at 26-28 weeks of gestation were included.

154 se infusion and oral glucose tolerance test (OGTT) before and 6 months after RDN.

155 ting, 24-h, and oral glucose tolerance test (OGTT) blood glucose, plasma insulin, and C-peptide level

156 ption during an oral glucose tolerance test (OGTT) for 400 northern European mothers at approximately

157 fasting and 2-h oral-glucose-tolerance test (OGTT) glucose and insulin concentrations were also measu

158 confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of gestation, but it is still un

159 (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessions.

160 sured during an oral glucose tolerance test (OGTT) in 552 nondiabetic participants in the Amish Famil

161 hanges after an oral glucose tolerance test (OGTT) in a community-based population.

162 e meal than the oral glucose tolerance test (OGTT) in all subgroups regardless of whether they had ab

163 efficacy in an oral glucose tolerance test (OGTT) in lean mice.

164 activity in an oral glucose tolerance test (OGTT) in normal and diabetic mice.

165 ds and after an oral glucose tolerance test (OGTT) in the European Atherosclerosis Research Study II

166 nderwent a 75-g oral glucose tolerance test (OGTT) in which we measured glucose tolerance, IR, and su

167 ng and 2-h post-oral-glucose-tolerance test (OGTT) insulin, the homeostasis model assessment of insul

168 subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days with the use of a randomized cr

169 itivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments.

170 hour and 2-hour oral glucose tolerance test (OGTT) results, with measurement of glucose and insulin l

171 e results of an oral glucose tolerance test (OGTT) routinely performed before surgery and 1 and/or 5

172 imals during an oral glucose tolerance test (OGTT) such that levels were indistinguishable from those

173 y was to use an oral glucose tolerance test (OGTT) to risk stratify for NODAT and IGT in renal transp

174 ciations with 5 oral glucose tolerance test (OGTT) traits in 427 nondiabetic Amish subjects, and 2) i

175 response to an oral glucose tolerance test (OGTT) was not affected.

176 weekly, and an oral glucose tolerance test (OGTT) was performed at study's end.

177 The 5-hour oral glucose tolerance test (OGTT) was performed to assess cerebral function and syst

178 OT) results, an oral glucose tolerance test (OGTT) was performed to diagnose GDM.

179 each visit, an oral-glucose-tolerance test (OGTT) was performed.

180 An oral glucose tolerance test (OGTT) was used to evaluate glucose control 3 weeks after

181 GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose t

182 nk before a 2-h oral-glucose-tolerance test (OGTT) would lower blood glucose concentrations.

183 (IGR) at 30-min oral glucose tolerance test (OGTT), a frequently used surrogate of first-phase insuli

184 nd underwent an oral glucose tolerance test (OGTT), a hypoglycemia questionnaire, and continuous gluc

185 formed using an oral glucose tolerance test (OGTT), although a non-fasting, glucose challenge test (G

186 AUCs) during an oral glucose tolerance test (OGTT), and blood lipids in the two groups before and aft

187 s had an oral glucose (75 g) tolerance test (OGTT), and GDM diagnosis was based on diagnostic criteri

188 els in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chronic dosing.

189 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide an

190 ivity during an oral glucose tolerance test (OGTT), hyperinsulinemic-euglycemic clamp, other measures

191 responses to an oral glucose tolerance test (OGTT), insulin sensitivity evaluated via hyperinsulinemi

192 ) underwent 5-h oral glucose tolerance test (OGTT), isoglycemic intravenous glucose infusion, and gra

193 ted using a 2-h oral glucose tolerance test (OGTT), with 7 samples of plasma glucose and serum insuli

194 ein we describe oral glucose tolerance test (OGTT)-modeled beta-cell function and incretin effect in

195 erived from the oral glucose tolerance test (OGTT).

196 ucose during an oral glucose tolerance test (OGTT).

197 studied with an oral glucose tolerance test (OGTT).

198 responses to an oral glucose tolerance test (OGTT).

199 )) underwent an oral glucose tolerance test (OGTT).

200 ns after a 75-g oral glucose tolerance test (OGTT).

201 3-hour 100-gram oral glucose tolerance test (OGTT).

202 rarely utilized oral glucose tolerance test (OGTT).

203 s before a 75-g oral glucose tolerance test (OGTT).

204 g/dL) during an oral glucose tolerance test (OGTT).

205 0 min before an oral glucose tolerance test (OGTT).

206 tested after an oral glucose tolerance test (OGTT).

207 subjected to an oral glucose tolerance test (OGTT); blood glucose increased (P<0.05) in control pigs

208 maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for Model 1 covariates, maternal

209 sion, a 240-min oral-glucose-tolerance test (OGTT; 75 g) was administered.

210 glucose from an oral glucose tolerance test [OGTT] [DM2h], n = 80; newly diagnosed diabetes by fastin

211 acterized by oral glucose tolerance testing (OGTT) and National Diabetes Data Group criteria.

212 Oral glucose tolerance testing (OGTT) has been mooted as an alternative but is inconveni

213 derwent 75-g oral glucose tolerance testing (OGTT), body composition analysis (dual-energy X-ray abso

214 ls underwent oral glucose tolerance testing (OGTT).

215 ents underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (baseline) and then in 2011 to 201

216 gone 2 or more oral glucose tolerance tests (OGTT) using grouped analyses and a continuous mixed-mode

217 explored with oral glucose tolerance tests (OGTT), serum lipid profiles, magnetic resonance imaging

218 mol/l on their oral glucose tolerance tests (OGTT).

219 glucose and/or oral glucose tolerance tests (OGTT).

220 ral and intravenous glucose tolerance tests (OGTT; IVGTT), hyperinsulinemic-euglycemic clamps, and me

221 sampled intravenous glucose tolerance tests (OGTTs and FSIGTs), hyperinsulinemic-euglycemic clamps wi

222 , we performed oral glucose tolerance tests (OGTTs) and euglycemic-insulinemic clamp studies in Zucke

223 Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolera

224 Oral glucose tolerance tests (OGTTs) and intravenous glucose tolerance tests (IVGTTs)

225 ng 2-hour 75-g oral glucose tolerance tests (OGTTs) at study baseline (6-9 weeks postpartum) and annu

226 Oral glucose tolerance tests (OGTTs) from differing states of glycemia were compared w

227 se levels from oral glucose tolerance tests (OGTTs) in pregnancy have not been assessed in a large sa

228 g standardized oral glucose-tolerance tests (OGTTs) performed in at-home settings.

229 3 months, and oral glucose tolerance tests (OGTTs) were performed annually to detect diabetes.

230 Oral-glucose-tolerance tests (OGTTs) were performed before and immediately after the d

231 underwent 5-h oral glucose tolerance tests (OGTTs), graded glucose infusion, and hyperinsulinemic-eu

232 lucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon

233 tered prior to oral glucose tolerance tests (OGTTs).

234 uently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29 recruited participants complet

235 The OGTT combined with transcriptomics can be used to measur

236 nd correlated with glucose levels across the OGTT (R = 0.44, P < 0.001) but was independent of fat ma

237 Although the OGTT is the "gold standard" for diagnosing diabetes, it

238 clamp performed with [3-(3)H]glucose and the OGTT and related to IR: peripheral (glucose uptake durin

239 The ingestion of saccharin before the OGTT did not alter any of the measured variables but eli

240 [(18)F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of glucose absorption (RaO) and dispo

241 e area under the curve (AUC) measured by the OGTT (AUC percentage change from supplementation baselin

242 ucose tolerance status was determined by the OGTT.

243 +/- 5 mg/dl), mean plasma glucose during the OGTT (290 +/- 9 to 225 +/- 6 mg/dl), HbA(1c) (8.5 +/- 0.

244 than G(L)-overexpressing HF rats during the OGTT (419 versus 117 microg of glycogen/mg of protein, r

245 6 +/- 50 micro Eq/l) and mean FFA during the OGTT (644 +/- 41 to 471 +/- 35 micro Eq/l) (both P < 0.0

246 e responses over the first 30 min during the OGTT (DeltaI(30)/DeltaG(30)).

247 earance both fasting (r=0.34) and during the OGTT (r=0.40, all P <0.002).

248 This was done during fasting, during the OGTT at 30, 60, and 120 min, and during the MMT at 60, 1

249 es in glucose or insulin measures during the OGTT between the 2 groups, but there was a trend for imp

250 and stimulated betatrophin levels during the OGTT in all three patient groups.

251 n indexes were reduced (P < 0.01) during the OGTT in the impaired glucose tolerance groups, indicatin

252 During the OGTT the incremental AUC for glucose from postinfusion b

253 als; however, the AUC of glucagon during the OGTT was also significantly greater in HYPER (19,303 +/-

254 e increased and their suppression during the OGTT was impaired.

255 nsulin area under the curve (AUC) during the OGTT was significantly reduced after 6 months of DHEA th

256 al and dynamic betatrophin levels during the OGTT were lower than in the obese or normal-weight pregn

257 emic profile and insulin response during the OGTT were normal.

258 ups of obese mice, glucose levels during the OGTT were substantially increased compared with those in

259 During the OGTT, basal and dynamic betatrophin levels at 60' were p

260 Based on the C-peptide response during the OGTT, increased CHO-induced insulin secretion is one pos

261 beta-Cell function during the OGTT, significantly blunted prior to RYGBP, normalized t

262 During the OGTT, the MCR(I) was suppressed within 15-30 min in NGT

263 qual amounts of CHO were consumed during the OGTT, the MUFA group had significantly higher C-peptide

264 agon concentrations were measured during the OGTT.

265 to or greater than those present during the OGTT.

266 a maximum of ~3.4 mM (P < 0.001) during the OGTT.

267 ured at baseline and every 30 min during the OGTT.

268 (P=0.004 and 0.07, respectively) during the OGTT.

269 ncentration curves, respectively, during the OGTT.

270 nd the insulin secretory response during the OGTT.

271 cterize nonsuppressed glucagon120 during the OGTT.

272 eased and triglycerides increased during the OGTT.

273 insulin-deficient Gcgr(-/-) mice during the OGTT.

274 Upon ER, the OGTT resulted in a faster and more pronounced down-regul

275 DJB improved the OGTT significantly (P < 0.001) compared with sham-operat

276 at of glucose during the first 30 min of the OGTT (delta IRI[30 min-0 min]/delta glucose[30 min-0 min

277 in effect was calculated as the ratio of the OGTT-betaCGS to the 2-h hyperglycemic clamp-betaCGS.

278 ty was 100% compared with the results of the OGTT.

279 his value, regardless of the findings on the OGTT.

280 t eliminated the effects of lactisole on the OGTT.The pharmacologic inhibition of STRs in the gastroi

281 Since the OGTT studies were performed on 20-h fasted rats, this me

282 cagon ratio.The addition of lactisole to the OGTT caused increases in the plasma responses of insulin

283 When this cutpoint was reapplied to the OGTT results, of those subjects with an HbA1c level of a

284 The large increase of ISR response to the OGTT together with the restoration of the first-phase in

285 the C-482T (IRE) determined response to the OGTT, with carriers of the rare T-482 having significant

286 d a full neuropsychological battery prior to OGTT.

287 entially affect postprandial and response to OGTT and suggest a novel mechanism for the effects of va

288 ased 67% (28 weeks), and insulin response to OGTT was decreased by 50%.

289 fect and inappropriate glucagon responses to OGTT.

290 m 3 months, HbA1c had similar sensitivity to OGTT and represents a convenient alternative.

291 [SD] body mass index, 26.6 [4.6]) underwent OGTT at a median (IQR) 6.5 (4.8-8.2) months postpartum.

292 enotyped for the E23K variant also underwent OGTTs.

293 s detected in 46% with CapBG versus 12% with OGTT (P=0.013), 4% with HbA1c (P<0.001), and 0% with FPG

294 as present in 14% with HbA1c versus 20% with OGTT (P=0.600) and 2% with FPG (P=0.059; n=50), whereas,

295 AT was found in 4% with HbA1c versus 6% with OGTT (P=1.00) and 2% with FPG (P=0.618; n=51).

296 rs2237457 was also strongly associated with OGTT glucose area under the curve in nondiabetic subject

297 olites tested, 91 significantly changed with OGTT (P </= 0.0005 for all).

298 71, located in FHIT) showed replication with OGTT traits and also in another population.

299 fore, MS has to be considered in tandem with OGTT results to assess cardiovascular risk.

300 d with subsequent nondiabetic OGTTs and with OGTTs performed at diagnosis.